Real-World Comparison of BCL2 Inhibitor and BTK Inhibitor Therapy in the Front-Line Treatment of CLL Including Patients with Del(17p)/TP53 Mutation

被引：0

作者：

Ermann, Daniel A. ^{[1
]}

Vardell, Victoria A. ^{[2
]}

Bock, Allison M. ^{[1
]}

Horns, Joshua J. ^{[3
]}

Shah, Harsh R. ^{[1
]}

Fitzgerald, Lindsey ^{[1
]}

Hu, Boyu ^{[1
]}

Kittai, Adam S. ^{[4
]}

Stephens, Deborah M. ^{[5
]}

机构：

[1] Univ Utah, Huntsman Canc Inst, Salt Lake City, UT USA

[2] Univ Utah, Huntsman Canc Inst, Div Hematol & Hematol Malignancies, Salt Lake City, UT USA

[3] Univ Utah, Dept Surg, Salt Lake City, UT USA

[4] Icahn Sch Med Mt Sinai, New York, NY USA

[5] Univ North Carolina, Chapel Hill, NC USA

来源：

关键词：

D O I：

10.1182/blood-2024-204134

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：1864 / 1865

页数：2